Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects (Q47739163)

5 February 2018

http://europepmc.org/abstract/MED/29322280

title

Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects (English)

1 reference

5 February 2018

http://europepmc.org/abstract/MED/29322280

author

Ahmed F El-Yazbi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29322280%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Abdullah Kaplan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29322280%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Emna Abidi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29322280%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Ali Eid

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29322280%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

George W Booz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29322280%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Fouad A Zouein

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29322280%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

publication date

11 January 2018

1 reference

5 February 2018

http://europepmc.org/abstract/MED/29322280

published in

Heart Failure Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29322280%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29322280%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29322280%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

419-437

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29322280%20AND%20SRC:MED&resulttype=core&format=json

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Long-term complications of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Projections of global mortality and burden of disease from 2002 to 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Management of type 2 diabetes: new and future developments in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Na(+)-D-glucose cotransporter in muscle capillaries increases glucose permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

SGLT2 inhibitors: the latest "new kids on the block"!

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Molecular mechanisms of diabetic vascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Metabolic memory: a vascular perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Metformin and Myocardial Injury in Patients With Diabetes and ST-Segment Elevation Myocardial Infarction: A Propensity Score Matched Analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Acute hyperglycemia in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Admission and fasting plasma glucose for estimating risk of death of diabetic and nondiabetic patients with acute coronary syndrome: nonlinearity of hazard ratios and time-dependent comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Admission glucose level and in-hospital outcomes in diabetic and non-diabetic patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Cardiovascular autonomic neuropathies as complications of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Autonomic imbalance: prophet of doom or scope for hope?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

In rats the duration of diabetes influences its impact on cardiac autonomic innervations and electrophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Na⁺ transport in the normal and failing heart - remember the balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Molecular mechanisms of diabetic cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Na+/Ca2+ exchange and Na+/K+-ATPase in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Cardiac excitation-contraction coupling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Targeting Na+/H+ exchanger regulation for cardiac protection: a RSKy approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

The Role of Sodium-Hydrogen Ion Exchange in Patients Undergoing Coronary Artery Bypass Grafting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Serum and glucocorticoid-responsive kinase-1 regulates cardiomyocyte survival and hypertrophic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Regulation of ion channels by the serum- and glucocorticoid-inducible kinase SGK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Increased myocardial uptake of dietary fatty acids linked to cardiac dysfunction in glucose-intolerant humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Active and inactive forms of pyruvate dehydrogenase in rat heart and kidney: effect of diabetes, fasting, and refeeding on pyruvate dehydrogenase interconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Adaptive increase in pyruvate dehydrogenase kinase 4 during starvation is mediated by peroxisome proliferator-activated receptor alpha.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

A murine model of isolated cardiac steatosis leads to cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Lipotoxic heart disease in obese rats: implications for human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Contribution of polyol pathway to diabetes-induced oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Advanced protein glycosylation in diabetes and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Functional deficiencies of subsarcolemmal mitochondria in the type 2 diabetic human heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Role of mitochondrial dynamics proteins in the pathophysiology of obesity and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Mitochondrial metabolism of reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Alteration of the phosphocreatine energy shuttle components in diabetic rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Myocardial substrate metabolism in the normal and failing heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

beta-Hydroxybutyrate inhibits myocardial fatty acid oxidation in vivo independent of changes in malonyl-CoA content

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Ketone body metabolism and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Epicardial adipose tissue and insulin resistance in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

SGLT-2 inhibition and glucagon: Cause for alarm?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Oxidative stress: a key contributor to diabetic cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Diabetes, oxidative stress and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Metabolic syndrome, inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Endothelial dysfunction - a major mediator of diabetic vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Arachidonate 12/15-lipoxygenase-induced inflammation and oxidative stress are involved in the development of diabetic cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

The heme oxygenase system selectively enhances the anti-inflammatory macrophage-M2 phenotype, reduces pericardial adiposity, and ameliorated cardiac injury in diabetic cardiomyopathy in Zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

N-Acetylcysteine and allopurinol up-regulated the Jak/STAT3 and PI3K/Akt pathways via adiponectin and attenuated myocardial postischemic injury in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Altered macrophage differentiation and immune dysfunction in tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Sodium-coupled glucose transporter as a functional glucose sensor of retinal microvascular circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Glucose and glucose transporters regulate lymphatic pump activity through activation of the mitochondrial ATP-sensitive K+ channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Low Glucose Enhances Na + /Glucose Transport in Bovine Brain Artery Endothelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Hypoxia-induced increase in intracellular calcium concentration in endothelial cells: role of the Na(+)-glucose cotransporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

A functional role for sodium-dependent glucose transport across the blood-brain barrier during oxygen glucose deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Acute effects of glucose and insulin on vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Perivascular adipose tissue, inflammation and insulin resistance: link to vascular dysfunction and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

M1 and M2 macrophage proteolytic and angiogenic profile analysis in atherosclerotic patients reveals a distinctive profile in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

The pathophysiology of heart failure with preserved ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

The pathophysiology of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Obesity and the obesity paradox in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

SGLT2 inhibitors in the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

EMPA-REG OUTCOME: The Cardiologist's Point of View

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Inhibition of SGLT1 abrogates preconditioning-induced cardioprotection against ischemia-reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-017-9665-9

Measurement of myocardial glycogen synthesis in diabetic and fasted rats

21 January 2018

1 reference

12 December 2020

Ketone body production and disposal: effects of fasting, diabetes, and exercise.

1 reference

12 December 2020

Diabetes decreases Na+-K+ pump concentration in skeletal muscles, heart ventricular muscle, and peripheral nerves of rat

1 reference

12 December 2020

Dynamics of insulin action on mammary epithelium.

1 reference

12 December 2020

Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction

1 reference

12 December 2020

Regulation of alternative pathways of glucose metabolism in rat heart in alloxan diabetes: Changes in the pentose phosphate pathway

1 reference

12 December 2020

Insulin-stimulated glucose transport inhibits Ca2+ influx and contraction in vascular smooth muscle

1 reference

12 December 2020

Insulin, ketone bodies, and mitochondrial energy transduction.

1 reference

12 December 2020

Preischaemic as well as postischaemic application of a Na+/H+ exchange inhibitor reduces infarct size in pigs

1 reference

12 December 2020

Substrate signaling by insulin: a ketone bodies ratio mimics insulin action in heart

1 reference

12 December 2020

A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion

1 reference

12 December 2020

Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Inf

1 reference

12 December 2020

Decrease in sodium-calcium exchange and calcium currents in diabetic rat ventricular myocytes

1 reference

12 December 2020

Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells

1 reference

12 December 2020

Cardioprotective effects of the Na(+)/H(+) exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA

1 reference

12 December 2020

Diminished function and expression of the cardiac Na+-Ca2+ exchanger in diabetic rats: implication in Ca2+ overload

1 reference

12 December 2020

Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators

1 reference

12 December 2020

Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes

1 reference

12 December 2020

Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging

1 reference

12 December 2020

Free radicals and antioxidants in human health: current status and future prospects.

1 reference

12 December 2020

Intracellular sodium increase and susceptibility to ischaemia in hearts from type 2 diabetic db/db mice

1 reference

12 December 2020

Alloxan-induced diabetes reduces sarcolemmal Na+-K+ pump function in rabbit ventricular myocytes

1 reference

12 December 2020

Hexosamine biosynthetic pathway flux and cardiomyopathy in type 2 diabetes mellitus. Focus on "Impact of type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart"

1 reference

12 December 2020

The impact of admission plasma glucose on long-term mortality after STEMI and NSTEMI myocardial infarction

1 reference

12 December 2020

Enhanced activity of the myocardial Na+/H+ exchanger contributes to left ventricular hypertrophy in the Goto-Kakizaki rat model of type 2 diabetes: critical role of Akt

1 reference

12 December 2020

Effects of phlorizin on vascular complications in diabetes db/db mice.

1 reference

12 December 2020

The NLRP3 inflammasome and diabetic cardiomyopathy : editorial to: "Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model" by Beibei Luo et al

1 reference

12 December 2020

Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model

1 reference

12 December 2020

Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart

1 reference

12 December 2020

Dapagliflozin reduces the amplitude of shortening and Ca(2+) transient in ventricular myocytes from streptozotocin-induced diabetic rats

1 reference

12 December 2020

Jardiance (Empagliflozin), an SGLT2 Inhibitor, Receives FDA Approval for the Treatment of Patients with Type 2 Diabetes

1 reference

12 December 2020

10.1007/S10741-017-9665-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29322280%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference